[HTML][HTML] Impact of BMI and gender on outcomes in DLBCL patients treated with R-CHOP: a pooled study from the LYSA
C Sarkozy, N Mounier, A Delmer, A Van Hoof… - Lymphoma, 2014 - hindawi.com
In diffuse large B-cell lymphoma (DLBCL), the age-adjusted International Prognostic Index
(aaIPI) score is currently used to predict patient outcomes and to choose the best therapeutic …
(aaIPI) score is currently used to predict patient outcomes and to choose the best therapeutic …
MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma …
J Wang, M Zhou, JY Xu, YG Yang, QG Zhang, RF Zhou… - 2016 - digitum.um.es
The International Prognostic Index (IPI) has been the basis for determining prognosis in
patients with diffuse large B-cell lymphoma (DLBCL) for the past 20 years. The utility of the …
patients with diffuse large B-cell lymphoma (DLBCL) for the past 20 years. The utility of the …
[HTML][HTML] Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma …
LH Sehn, M Chhanabhai, C Fitzgerald, K Gill… - Blood, 2005 - Elsevier
Background: The IPI, which was developed prior to the availability of rituximab, remains the
primary clinical tool used to predict outcome for patients with DLBCL. Since clinical trials …
primary clinical tool used to predict outcome for patients with DLBCL. Since clinical trials …
Reassessment of the prognostic value of the International Prognostic Index and the revised International Prognostic Index in patients with diffuse large B-cell …
HH Huang, F Xiao, FY Chen… - Experimental and …, 2012 - spandidos-publications.com
Abstract The International Prognostic Index (IPI) is a widely accepted model that is used to
predict the prognosis of patients with diffuse large B‑cell lymphoma (DLBCL) who are …
predict the prognosis of patients with diffuse large B‑cell lymphoma (DLBCL) who are …
Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B‐cell lymphoma in the rituximab era
R Watanabe, N Tomita, M Itabashi… - European journal of …, 2014 - Wiley Online Library
Objectives The tumor microenvironment, including tumor‐infiltrating lymphocytes and
myeloid‐derived cells, is an important factor in the pathogenesis and clinical behavior of …
myeloid‐derived cells, is an important factor in the pathogenesis and clinical behavior of …
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R …
LH Sehn, B Berry, M Chhanabhai, C Fitzgerald, K Gill… - Blood, 2007 - ashpublications.org
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity, with patients exhibiting a
wide range of outcomes. The addition of rituximab to CHOP chemotherapy (R-CHOP) has …
wide range of outcomes. The addition of rituximab to CHOP chemotherapy (R-CHOP) has …
External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free …
N Warnnissorn, N Kanitsap, P Niparuck… - …, 2022 - Taylor & Francis
Background Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive
lymphoma. The standard first-line therapy for DLBCL consists of rituximab …
lymphoma. The standard first-line therapy for DLBCL consists of rituximab …
The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of …
JH Park, DH Yoon, DY Kim, S Kim, S Seo, Y Jeong… - Annals of …, 2014 - Springer
Abstract Although the International Prognostic Index (IPI) is considered as the current
standard prognostication system for diffuse large B-cell lymphoma (DLBCL), prognostic …
standard prognostication system for diffuse large B-cell lymphoma (DLBCL), prognostic …
The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP
JJ Castillo, BE Beltran, MK Song, I Ilic, S Leppa… - Leukemia research, 2012 - Elsevier
Our objective was to evaluate the non-germinal center (GC) profile as a marker for response
and survival in DLBCL and to compare the characteristics of patients with GC and non-GC …
and survival in DLBCL and to compare the characteristics of patients with GC and non-GC …
Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution
MQ Salas, S Mercadal… - Leukemia & …, 2020 - Taylor & Francis
The discriminative power of International Prognostic Index (IPI) in diffuse large B-cell
lymphoma (DLBCL) decreased with the addition of rituximab to chemotherapy. The National …
lymphoma (DLBCL) decreased with the addition of rituximab to chemotherapy. The National …